Abstract Library

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4584 Hepatic cytoreduction in advanced lung neuroendocrine neoplasms: A single institutional case series

Introduction: Role of hepatic cytoreductive surgery in well-differentiated gastroenteropancreatic neuroendocrine neoplasms (NENs) with liver metastases is well-described, however, its role in advanced lung NENs with liver metastases is unknown.

Conference:

Presenting Author: Grewal U

Authors: Grewal U, Patel R, Furqan M, Dillon J, Chandasekharan C,

Keywords: Lung neuroendocrine neoplasm, Hepatic cytoreductive surgery,

#4305 Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,

#4206 Specific spliceosomic landscapes reveal a possible link between RNA processing and panNETs behaviour

Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) are characterized by a low number of mutations. Despite genomics, transcriptomics and epigenomics studies have helped to understand the molecular features of PanNETs, there is still a vast unexplored ground for better comprehension of this disease. In this context, we have previously documented that RNA splicing is dysregulated in these tumors, which unveils new avenues to discover potential biomarkers and therapeutic targets. However, clinical and molecular implications of this dysregulation are still very poorly understood.

Conference:

Presenting Author: Pedraza-Arévalo S

Authors: Pedraza-Arévalo S, Blázquez-Encinas R, García-Vioque V, Moreno-Montilla M, Ruiz-Palacios D,

Keywords: pancreatic neuroendocrine tumor, splicing, RNA, grade, metastasis,

#4094 Peptide Receptor Radionuclide Therapy improves progression free and overall survival in patients who progress after resection of gastroenteropancreatic NETs

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) improves progression-free-survival (PFS) in advanced midgut neuroendocrine tumors (NETs). Whether PRRT specifically improves survival in surgically managed gastroenteropancreatic (GEP) NET with progression is unknown.

Conference:

Presenting Author: Howe J

Authors: Borbon L, Sherman S, Breheny P, Ear P, Menda Y,

Keywords: gastroenteropancreatic, resection, progression, PRRT, neuroendocrine tumor,